# KEYNOTE-630 (NCT03833167)

> Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03833167
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Squamous Cell
- Interventions: Pembrolizumab; Placebo
- Enrollment: 450
- Primary outcome: Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 9
- Podcasts: 8
- X threads: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-630-nct03833167

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03833167", "email": "<work email>"}; the inbox owner confirms by the emailed link.